Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | GPR3 | P46089 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GFER | P55789 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL242206 | 1.00 | ERAP1 (0.51) | ERAP1KDM4EMAPTALDH1A1L3MBTL1 | |
| SCHEMBL23641666 | 0.98 | ERAP1 (0.49) | ERAP1KDM4EMAPTALDH1A1L3MBTL1 | |
| Bromide SCHEMBL5145384 | 0.96 | ERAP1 (0.47) | ERAP1KDM4EMAPTALDH1A1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL28409885 | 0.96 | ERAP1 (0.47) | ERAP1KDM4EMAPTALDH1A1L3MBTL1 | |
| SCHEMBL31093213 | 0.91 | ERAP1 (0.47) | ERAP1KDM4EMAPTALDH1A1L3MBTL1 | |
| SCHEMBL26106884 | 0.91 | ERAP1 (0.47) | ERAP1KDM4EMAPTALDH1A1L3MBTL1 | |
| SCHEMBL1049324 | 0.75 | ERAP1 (0.50) | ERAP1KDM4EMAPTALDH1A1L3MBTL1 | |
| Water SCHEMBL21823213 | 0.73 | ERAP1 (0.49) | ERAP1KDM4EMAPTALDH1A1L3MBTL1 | |
| Iodide SCHEMBL9134481 | 0.73 | PTPN1 (0.50) | ERAP1KDM4EMAPTALDH1A1L3MBTL1 | |
| SCHEMBL13173865 | 0.73 | ERAP1 (0.53) | ERAP1KDM4EMAPTALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260008803-A1 | SIALIDASE-RESISTANT SACCHARIDE AND METHOD OF MAKING AND USING THE SAME | ACADEMIA SINICA (TW) | 2026-01-08 | — | — | US | disclosed |
| US-20250320255-A1 | UNIVERSAL ADJUVANT FOR NASAL, ORAL, AND INTRAMUSCULAR DELIVERY OF VACCINES | DESIGN ZYME LLC (US) | 2025-10-16 | — | — | US | disclosed |
| US-12384811-B2 | Sialidase-resistant saccharide and method of making and using the same | ACADEMIA SINICA (TW) | 2025-08-12 | — | — | US | disclosed |
| EP-4531908-A1 | UNIVERSAL ADJUVANT FOR NASAL, ORAL, AND INTRAMUSCULAR DELIVERY OF VACCINES | Design-Zyme LLC (US) | 2025-04-09 | — | — | EP | disclosed |
| US-12110532-B2 | In vitro glycosylation of proteins and enzymes | DESIGN- ZYME LLC (US) | 2024-10-08 | — | — | US | disclosed |
| WO-2023230241-A9 | UNIVERSAL ADJUVANT FOR NASAL, ORAL, AND INTRAMUSCULAR DELIVERY OF VACCINES | Design-Zyme LLC (US) | 2024-09-19 | — | — | WO | disclosed |
| US-20240191272-A1 | METHOD FOR PRODUCING ANTIBODY-DRUG CONJUGATE AND ENZYME USED FOR THE SAME | MICROBIOPHARM JAPAN CO., LTD. (JP) | 2024-06-13 | — | — | US | disclosed |
| US-20240139312-A1 | UNIVERSAL ADJUVANT FOR NASAL, ORAL, AND INTRAMUSCULAR DELIVERY OF VACCINES | Design-Zyme LLC | 2024-05-02 | — | — | US | disclosed |
| EP-4316527-A1 | METHOD FOR MANUFACTURING ANTIBODY-DRUG CONJUGATE AND ENZYME USED FOR SAME | MicroBiopharm Japan Co., Ltd. (JP) | 2024-02-07 | — | — | EP | disclosed |
| WO-2023230241-A1 | UNIVERSAL ADJUVANT FOR NASAL, ORAL, AND INTRAMUSCULAR DELIVERY OF VACCINES | Design-Zyme LLC (US) | 2023-11-30 | — | — | WO | disclosed |
| US-20230203557-A1 | IN VITRO GLYCOSYLATION OF PROTEINS AND ENZYMES | Design-Zyme LLC (US) | 2023-06-29 | — | — | US | disclosed |
| US-11643676-B2 | In vitro glycosylation of proteins and enzymes | Design-Zyme LLC (US) | 2023-05-09 | — | — | US | disclosed |
| CN-116064705-A | Method for preparing Fc-containing molecules with reconstituted sugar chains | 第一三共株式会社 | 2023-05-05 | — | — | CN | disclosed |
| EP-4159749-A2 | A METHOD FOR PRODUCING FC-CONTAINING MOLECULE WITH REMODELED SUGAR CHAIN | Daiichi Sankyo Company, Limited (JP) | 2023-04-05 | — | — | EP | disclosed |
| CN-110002967-B | Method for producing halide, method for producing potassium salt, and potassium salt | 株式会社大赛璐 | 2022-12-16 | — | — | CN | disclosed |
| WO-2022211075-A1 | METHOD FOR MANUFACTURING ANTIBODY-DRUG CONJUGATE AND ENZYME USED FOR SAME | 日本マイクロバイオファーマ株式会社 | 2022-10-06 | — | — | WO | disclosed |
| US-20220267363-A1 | SIALIDASE-RESISTANT SACCHARIDE AND METHOD OF MAKING AND USING THE SAME | ACADEMIA SINICA (TW) | 2022-08-25 | — | — | US | disclosed |
| US-20220259580-A1 | ENZYMATIC HEXOSAMINIDATION OF LACTOSE | BASF SE (DE) | 2022-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220267363-A1 | SIALIDASE-RESISTANT SACCHARIDE AND METHOD OF MAKING AND USING THE SAME | NEU2, NEU3, NEU1 | ERAP1 434/4885KDM4E 2451/4885MAPT 4094/4885 |
| US-20250320255-A1 | UNIVERSAL ADJUVANT FOR NASAL, ORAL, AND INTRAMUSCULAR DELIVERY OF VACCINES | B3GNT2, ST3GAL3, MUC1 | ERAP1 2758/4885KDM4E 4709/4885MAPT 3320/4885 |
| US-20260008803-A1 | SIALIDASE-RESISTANT SACCHARIDE AND METHOD OF MAKING AND USING THE SAME | NEU2, ST6GAL1, NEU3 | ERAP1 819/4885KDM4E 3272/4885MAPT 2734/4885 |
| US-20230203557-A1 | IN VITRO GLYCOSYLATION OF PROTEINS AND ENZYMES | ALDH7A1, OGA, DAO | ERAP1 330/4885KDM4E 1484/4885MAPT 4794/4885 |
| US-12384811-B2 | Sialidase-resistant saccharide and method of making and using the same | NEU2, NEU3, NEU1 | ERAP1 434/4885KDM4E 2451/4885MAPT 4094/4885 |
| US-20240191272-A1 | METHOD FOR PRODUCING ANTIBODY-DRUG CONJUGATE AND ENZYME USED FOR THE SAME | ENGASE, GALE, MGAM | ERAP1 178/4885KDM4E 2771/4885MAPT 2241/4885 |
| US-20240139312-A1 | UNIVERSAL ADJUVANT FOR NASAL, ORAL, AND INTRAMUSCULAR DELIVERY OF VACCINES | B3GNT2, SIGLEC7, ST3GAL3 | ERAP1 3620/4885KDM4E 4787/4885MAPT 2925/4885 |
| US-12110532-B2 | In vitro glycosylation of proteins and enzymes | ALDH7A1, OGA, DAO | ERAP1 330/4885KDM4E 1484/4885MAPT 4794/4885 |
| US-11643676-B2 | In vitro glycosylation of proteins and enzymes | ALDH7A1, OGA, DAO | ERAP1 330/4885KDM4E 1484/4885MAPT 4794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.